BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 36182105)

  • 1. Pilot Trial of Homebound Hematopoietic Cell Transplantation.
    Landau HJ; Orlando E; Rodriguez ES; Applebaum A; Mitchell HR; Peled JU; Khan N; Funnell T; Chung D; Scordo M; Shah GL; LeStrange NJ; Hambright KA; McElrath CM; Cazeau N; Devlin SM; Perales MA; Giralt SA
    Transplant Cell Ther; 2022 Dec; 28(12):832.e1-832.e7. PubMed ID: 36182105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Performance Status and Hematopoietic Cell Transplantation Specific Comorbidity Index on Unplanned Admission Rates in Patients with Multiple Myeloma Undergoing Outpatient Autologous Stem Cell Transplantation.
    Obiozor C; Subramaniam DP; Divine C; Shune L; Singh AK; Lin TL; Abhyankar S; Chen GJ; McGuirk J; Ganguly S
    Biol Blood Marrow Transplant; 2017 Oct; 23(10):1641-1645. PubMed ID: 28603071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-Autologous Hematopoietic Cell Transplant Care in the "Home Sweet Home" Setting: A Treatment Paradigm Shift.
    Kharfan-Dabaja MA; Roy V; Murthy H; Fischer D; Mohty R; Greathouse A; Brown A; Moreno K; Godsey E; Higginbotham JM; Bartholomew A; Jackson A; Torres-Guzman RA; Forte AJ; Ailawadhi S; Dronca R; Maniaci M
    Hematol Oncol Stem Cell Ther; 2023 May; 16(4):407-411. PubMed ID: 37363981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness, Safety, and Cost Implications of Outpatient Autologous Hematopoietic Stem Cell Transplant for Multiple Myeloma.
    Marini J; Maldonado A; Weeda E; Neppalli A; Hashmi H; Edwards K
    Hematol Oncol Stem Cell Ther; 2023 May; 16(4):351-357. PubMed ID: 37363969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
    Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
    Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of frailty, melphalan pharmacokinetics, and pharmacogenetics on outcomes post autologous hematopoietic cell transplantation for multiple myeloma.
    Nampoothiri RV; Kasudhan KS; Patil AN; Malhotra P; Khadwal A; Prakash G; Jain A; Malhotra S; Verma Attri S; Varma N; Varma S; Lad DP
    Bone Marrow Transplant; 2019 Dec; 54(12):2088-2095. PubMed ID: 31406224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation.
    Afrough A; Saliba RM; Hamdi A; Honhar M; Varma A; Cornelison AM; Rondon G; Parmar S; Shah ND; Bashir Q; Hosing C; Popat U; Weber DM; Thomas S; Orlowski RZ; Champlin RE; Qazilbash MH
    Biol Blood Marrow Transplant; 2018 Nov; 24(11):2197-2203. PubMed ID: 30016656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fractionated stem cell infusions for patients with plasma cell myeloma undergoing autologous hematopoietic cell transplantation.
    Landau H; Wood K; Chung DJ; Koehne G; Lendvai N; Hassoun H; Lesokhin A; Hoover E; Zheng J; Devlin SM; Giralt S
    Leuk Lymphoma; 2016 Aug; 57(8):1781-5. PubMed ID: 26758672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mixed outpatient-inpatient autologous stem cell transplant for multiple myeloma: A cost-saving initiative in a resource constrained environment.
    Clemmons AB; Anderegg S
    J Oncol Pharm Pract; 2017 Jul; 23(5):384-388. PubMed ID: 27000280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the incidence of engraftment syndrome with different melphalan formulations in adult multiple myeloma and immunoglobulin light chain amyloidosis patients undergoing autologous hematopoietic cell transplantation.
    Kowalski KE; Wheeler SE; Adams CB; Voils SA; Richards AI
    J Oncol Pharm Pract; 2022 Mar; 28(2):274-281. PubMed ID: 33435822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Propylene Glycol-Free Melphalan in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Results of a Phase II Study.
    Sarosiek S; Lee MH; Doros G; Edwards CV; Quillen K; Brauneis D; Shelton AC; Sanchorawala V; Sloan JM
    Transplant Cell Ther; 2023 Nov; 29(11):695.e1-695.e7. PubMed ID: 37607644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective study of dysgeusia and related symptoms in patients with multiple myeloma after autologous hematopoietic cell transplantation.
    Scordo M; Shah GL; Adintori PA; Knezevic A; Devlin SM; Buchan ML; Preston EV; Lin AP; Rodriguez NT; Carino CA; Nguyen LK; Sitner NC; Barasch A; Klang MG; Maloy MA; Mastrogiacomo B; Carlow DC; Schofield RC; Slingerland AE; Slingerland JB; Stein-Thoeringer CK; Lahoud OB; Landau HJ; Chung DJ; van den Brink MRM; Peled JU; Giralt SA
    Cancer; 2022 Nov; 128(21):3850-3859. PubMed ID: 36041227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Family Caregiver Experiences in the Inpatient and Outpatient Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Settings: A Qualitative Study.
    Gray TF; Do KM; Amonoo HL; Sullivan L; Kelkar AH; Pirl WF; Hammer MJ; Tulsky JA; El-Jawahri A; Cutler CS; Partridge AH
    Transplant Cell Ther; 2024 Jun; 30(6):610.e1-610.e16. PubMed ID: 37783339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose chemotherapy and autologous stem cell transplantation of patients with multiple myeloma in an outpatient setting.
    Lisenko K; Sauer S; Bruckner T; Egerer G; Goldschmidt H; Hillengass J; Schmier JW; Shah S; Witzens-Harig M; Ho AD; Wuchter P
    BMC Cancer; 2017 Feb; 17(1):151. PubMed ID: 28228122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma.
    Giralt S; Garderet L; Durie B; Cook G; Gahrton G; Bruno B; Hari P; Lokhorst H; McCarthy P; Krishnan A; Sonneveld P; Goldschmidt H; Jagannath S; Barlogie B; Mateos M; Gimsing P; Sezer O; Mikhael J; Lu J; Dimopoulos M; Mazumder A; Palumbo A; Abonour R; Anderson K; Attal M; Blade J; Bird J; Cavo M; Comenzo R; de la Rubia J; Einsele H; Garcia-Sanz R; Hillengass J; Holstein S; Johnsen HE; Joshua D; Koehne G; Kumar S; Kyle R; Leleu X; Lonial S; Ludwig H; Nahi H; Nooka A; Orlowski R; Rajkumar V; Reiman A; Richardson P; Riva E; San Miguel J; Turreson I; Usmani S; Vesole D; Bensinger W; Qazilbash M; Efebera Y; Mohty M; Gasparreto C; Gajewski J; LeMaistre CF; Bredeson C; Moreau P; Pasquini M; Kroeger N; Stadtmauer E
    Biol Blood Marrow Transplant; 2015 Dec; 21(12):2039-2051. PubMed ID: 26428082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation.
    Sidiqi MH; Aljama MA; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dispenzieri A; Dingli D; Leung N; Gonsalves WI; Kapoor P; Kourelis TV; Hogan WJ; Wolf RC; Kumar SK; Gertz MA
    Bone Marrow Transplant; 2019 Jul; 54(7):1077-1081. PubMed ID: 30390060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma.
    Maloney DG; Molina AJ; Sahebi F; Stockerl-Goldstein KE; Sandmaier BM; Bensinger W; Storer B; Hegenbart U; Somlo G; Chauncey T; Bruno B; Appelbaum FR; Blume KG; Forman SJ; McSweeney P; Storb R
    Blood; 2003 Nov; 102(9):3447-54. PubMed ID: 12855572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complete remission of both immunoglobulin light chain amyloidosis and psoriasis after autologous hematopoietic stem cell transplantation: A case report.
    Chen W; Ren G; Zuo K; Huang X
    Medicine (Baltimore); 2018 Dec; 97(50):e13589. PubMed ID: 30558027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD34+ hematopoietic progenitor cell dose as a predictor of engraftment and survival in multiple myeloma patients undergoing autologous stem cell transplantation.
    Aladağ Karakulak E; Demiroğlu H; Büyükaşik Y; Turgut M; Aksu S; Sayinalp N; Haznedaroğlu IC; Özcebe OI; Göker H
    Turk J Med Sci; 2020 Dec; 50(8):1851-1856. PubMed ID: 32512672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.